These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or recommendations of Barron’s. Some of the reports’ issuers have provided, or hope to provide, investment-banking or other services to the companies being analyzed.
Pfizer
PFE-NYSE
Buy • Price $46.55 0n Oct. 31
by BofA Securities
Pfizer shares are trading higher today [Nov. 1]. after it reported better third-quarter results from higher revenue ($1.5 billion) and non-GAAP earnings per share (38 cents).
Source: https://www.barrons.com/articles/pfizer-stocks-post-covid-future-looks-healthy-51667601302?siteid=yhoof2&yptr=yahoo